Literature DB >> 21125280

Immunoglobulins during different treatment regimes in Schnitzler's syndrome.

Rene Thonhofer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21125280     DOI: 10.1007/s00296-010-1681-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  7 in total

1.  Schnitzler's syndrome with monoclonal IgG kappa gammopathy: good response to cyclosporin.

Authors:  M Pascual-López; A Hernández-Núñez; J Sánchez-Pérez; J Fernández-Herrera; A García-Díez
Journal:  J Eur Acad Dermatol Venereol       Date:  2002-05       Impact factor: 6.166

2.  Schnitzler's syndrome: successful treatment of two patients using thalidomide.

Authors:  M Worm; G Kolde
Journal:  Br J Dermatol       Date:  2003-03       Impact factor: 9.302

3.  Schnitzler's syndrome treated successfully with intravenous pulse cyclophosphamide.

Authors:  D Peterlana; A Puccetti; E Tinazzi; S Simeoni; C Lunardi
Journal:  Scand J Rheumatol       Date:  2005 Jul-Aug       Impact factor: 3.641

4.  Schnitzler's syndrome--exacerbation after anti-TNF treatment.

Authors:  R Thonhofer; E Uitz; W Graninger
Journal:  Rheumatology (Oxford)       Date:  2007-04-19       Impact factor: 7.580

5.  Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.

Authors:  H D de Koning; E J Bodar; A Simon; J C H van der Hilst; M G Netea; J W M van der Meer
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

6.  Report of a case of Schnitzler's syndrome treated successfully with interferon alpha 2b.

Authors:  Noël Emile Célestin Schartz; Suzanne Buder; Hans Sperl; Heike Audring; Ralph Paus; Beate Tebbe; Katharina Krüger; Wolfram Sterry
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

Review 7.  Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment.

Authors:  Heleen D de Koning; Evelien J Bodar; Jos W M van der Meer; Anna Simon
Journal:  Semin Arthritis Rheum       Date:  2007-06-21       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.